CAS 96102-27-1

Formule : C14H17F3N4O5

InChI : InChI=1S/C14H17F3N4O5/c15-14(16,17)12(24)19-3-1-2-7-5-21(13(25)20-11(7)18)10-4-8(23)9(6-22)26-10/h1-2,5,8-10,22-23H,3-4,6H2,(H,19,24)(H2,18,20,25)/b2-1+/t8-,9+,10+/m0/s1

Code InChI : WYMZPLFAGMLVFK-HFVMFMDWSA-N

SMILES : C1[C@@H]([C@H](O[C@H]1N2C=C(C(=NC2=O)N)/C=C/CNC(=O)C(F)(F)F)CO)O

TFA-aa-dC

CAS : 96102-27-1

TFA-aa-dC

Formule : C₁₄H₁₇F₃N₄O₅

Degré de pureté : ≥95%

Masse moléculaire : 378.3

Ref: 54-PC1046826

TFA-aa-dC

CAS : 96102-27-1

Formule : C₁₄H₁₇F₃N₄O₅

Masse moléculaire : 378.3038

Ref: IN-DA01EBQL

TFA-aa-dC

CAS : 96102-27-1

TFA-aa-dC is a novel anti-cancer drug that has been shown to have both antiviral and anticancer activities. It is a modified phosphoramidite of 2'-deoxyadenosine 5'-triphosphate with a 3'-amino group (TFA-aa-dC) and an acetyl group at the 2' position. TFA-aa-dC blocks viral replication by inhibiting the activity of viral DNA polymerase, which is required for DNA synthesis. The compound also inhibits cell growth by blocking RNA synthesis and protein production, leading to cell death. TFA-aa-dC has shown efficacy in preclinical studies against cervical cancer and leukemia cells.

Formule : C₁₄H₁₇F₃N₄O₅

Degré de pureté : Min. 95%

Masse moléculaire : 378.3 g/mol

Ref: 3D-NT57548